Clinical Stabilization of Hypercapnia: NIPPV v HVNI (NCT04709562) | Clinical Trial Compass
CompletedNot Applicable
Clinical Stabilization of Hypercapnia: NIPPV v HVNI
United States68 participantsStarted 2020-11-11
Plain-language summary
This study will evaluate the ability of High Velocity Nasal Insufflation \[HVNI\] to effect ventilation and related physiologic responses in hypercapnic patients when compared to noninvasive positive pressure ventilation \[NIPPV\].
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults, 18 years or older with a known or suspected diagnosis of COPD
* Presentation with acute hypercapnic respiratory failure
* Moderate to Severe patient baseline hypercarbia/hypercapnia, defined as a baseline PCO2 of 60 mmHg or higher
* Venous pH of 7.0 - 7.35
Exclusion Criteria:
* Severe metabolic derangements (e.g. suspected drug overdose, mixed acid/base disorder)
* Need for airway protection
* Primary condition of Congestive Heart Failure
* Need for emergent intubation
* Pneumonia diagnosis with significant infiltrate on chest x-ray that is clinically correlated with pneumonia
* Inability to provide informed consent
* Pregnancy
* Known contraindication to perform procedures listed, or therapies described in the protocol
* Respiratory arrest or significant respiratory depression on presentation
* Significant nasal occlusion either unilateral or bilateral
* Absence of spontaneous respiration or known contraindication to HVNI
* Extreme agitation or uncooperativeness that would hinder either arm of randomized therapy
* Determined by the clinician to be sufficiently unstable or unsuitable for this study
What they're measuring
1
Rated Perceived Dyspnea [RPD]
Timeframe: During four time points in the study over the course of four hours; Baseline, 30 min, 60 min, and 240 min